

(19)



(11)

**EP 4 011 915 B8**

(12)

**CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:

**Corrected version no 1 (W1 B1)**  
**Corrections, see**  
**Bibliography INID code(s) 73**

(51) International Patent Classification (IPC):

**C07K 16/28<sup>(2006.01)</sup> A61K 39/395<sup>(2006.01)</sup>**

(48) Corrigendum issued on:

**15.11.2023 Bulletin 2023/46**

(52) Cooperative Patent Classification (CPC):

**C07K 16/2866; A61K 39/39541; A61P 9/00;**  
**A61P 11/00; A61P 11/02; A61P 11/04;**  
**A61P 11/06; A61P 11/08; A61P 29/00;**  
**A61P 31/10; A61P 37/00; A61P 37/08;**  
**A61P 43/00; A61K 2039/505; A61K 2039/54;**

(45) Date of publication and mention of the grant of the patent:

**11.10.2023 Bulletin 2023/41**

(Cont.)

(21) Application number: **21199451.2**

(22) Date of filing: **20.08.2013**

(54) **METHODS FOR TREATING OR PREVENTING ASTHMA BY ADMINISTERING AN IL-4R ANTAGONIST**

VERFAHREN ZUR BEHANDLUNG ODER VERHINDERUNG VON ASTHMA DURCH VERABREICHUNG EINES IL-4R-ANTAGONISTEN

PROCÉDÉS DE TRAITEMENT OU DE PRÉVENTION DE L'ASTHME PAR ADMINISTRATION D'UN ANTAGONISTE IL-4R

(84) Designated Contracting States:

**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR**

(73) Proprietors:

- **Sanofi Biotechnology**  
**94250 Gentilly (FR)**
- **Regeneron Pharmaceuticals, Inc.**  
**Tarrytown, NY 10591-6707 (US)**

(30) Priority: **21.08.2012 US 201261691625 P**  
**29.01.2013 US 201361758097 P**  
**06.02.2013 US 201361761279 P**  
**14.03.2013 US 201361783796 P**  
**27.03.2013 US 201361805797 P**  
**16.07.2013 FR 1356994**

(72) Inventors:

- **ARDELEANU, Marius**  
**Tarrytown, NY 10591-6707 (US)**
- **GANDHI, Namita**  
**Tarrytown, NY 10591-6707 (US)**
- **GRAHAM, Neil**  
**Tarrytown, NY 10591-6707 (US)**
- **KIRKESSELI, Stephane C.**  
**Bridgewater, NJ 08807 (US)**
- **KUNDU, Sudeep**  
**Bridgewater, NJ 08807 (US)**
- **RADIN, Allen**  
**Tarrytown, NY 10591-6707 (US)**
- **ROCKLIN, Ross E.**  
**Bridgewater, NJ 08807 (US)**
- **WEINSTEIN, Steven P.**  
**Tarrytown, NY 10591-6707 (US)**

(43) Date of publication of application:

**15.06.2022 Bulletin 2022/24**

(60) Divisional application:

**23202532.0**

(62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC:

**18194745.8 / 3 470 432**  
**13759908.0 / 2 888 281**

**EP 4 011 915 B8**

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- DAVIDSON HAMILTON, Jennifer  
Tarrytown, NY 10591-6707 (US)
  - MING, Jeffrey  
Bridgewater, NJ 08807 (US)
- (74) Representative: **Zwicker, Jörk**  
**ZSP Patentanwälte PartG mbB**  
**Hansastraße 32**  
**80686 München (DE)**
- (56) References cited:  
**WO-A1-2010/053751**
- J. CORREN ET AL: "A Randomized, Controlled, Phase 2 Study of AMG 317, an IL-4R Antagonist, in Patients with Asthma", AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, vol. 181, no. 8, 15 April 2010 (2010-04-15), pages 788-796, XP055013586, ISSN: 1073-449X, DOI: 10.1164/rccm.200909-1448OC
  - JARED DARVEAUX ET AL: "Biologics in Asthma-The Next Step Toward Personalized Treatment", THE JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY : AN OFFICIAL JOURNAL OF AAAAI, AMERICAN ACADEMY OF ALLERGY ASTHMA & IMMUNOLOGY, vol. 3, no. 2, 1 March 2015 (2015-03-01), pages 152-160, XP055535036, ISSN: 2213-2198, DOI: 10.1016/j.jaip.2014.09.014
  - METERAN HOWRAMAN ET AL: "Novel monoclonal treatments in severe asthma", JOURNAL OF ASTHMA : DEVOTED TO ASTHMA AND RELATED CONDITIONS, INFORMA HEALTHCARE, USA, vol. 54, no. 10, 30 November 2017 (2017-11-30), pages 991-1011, XP009510079, ISSN: 1532-4303, DOI: 10.1080/02770903.2017.1296157 [retrieved on 2017-03-16]
  - DIEGO BAGNASCO ET AL: "A Critical Evaluation of Anti-IL-13 and Anti-IL-4 Strategies in Severe Asthma", INTERNATIONAL ARCHIVES OF ALLERGY AND IMMUNOLOGY., vol. 170, no. 2, 1 January 2016 (2016-01-01), pages 122-131, XP055535051, CH ISSN: 1018-2438, DOI: 10.1159/000447692
  - WENZEL SALLY ET AL: "Dupilumab in Persistent Asthma with Elevated Eosinophil Levels", THE NEW ENGLAND JOURNAL OF MEDICINE, MASSACHUSETTS MEDICAL SOCIETY, US, vol. 368, no. 26, 27 June 2013 (2013-06-27), pages 2455-2466, XP008165248, ISSN: 0028-4793, DOI: 10.1056/NEJMOA1304048 [retrieved on 2013-05-21]
- (52) Cooperative Patent Classification (CPC): (Cont.)  
C07K 2317/21